References
- Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzock, R. and Kantarjian, H.M. (1999) "Mechanisms of disease: The biology of chronic myeloid leukemia", New England Journal off Medicine, 341, 164–172.
- Sawyers, C.L. (1999) "Chronic myeloid leukemia", New England Journal of Medicine, 340, 1330— 1340.
- Druker, B.J., Sawyers, CL., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., et al. (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", New England Journal off Medicine, 344, 1038 — 1042.
- Druker, B.J., Talpaz, M., Resta, Di., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal off Medicine, 344, 1031 — 1037.
- Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. (2002) "Hematologic and cytoge-netic responses to imatinib mesylate in chronic myelogenous leukemia". New England Journal of Medicine, 346, 645–652.
- Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study", Blood, 99, 1928 — 1937.
- Kantarjian, H., Jorge, C., O'Brien, S., Francis, J., Giles, F.J., Albitar, M., et al. (2002) "Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase", Blood, 99, 3547 — 3553.
- O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", New England Journal of Medicine, 348, 994 — 1004.
- Petzer, AL., Gunsilius, E., Hayes, M., Stockhammer, G., Duba, H.C.H., Schneller, F., et al. (2002) "Low concentrations of STI571 in the cerebrospinal fluid: a case report", British Journal of Haematology, 117, 623–625.
- Takayama, N., Sato, N., O'Brien, S.G., Ikeda, Y. and Okamoto, S. (2002) "Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid", British Journal of Haematology, 119, 106 — 108.
- Kantarjian, H.M., O'Brien, S., Smith, T.L., Cortes, J., Giles, F.J., Beran, M., et al. (2000) "Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia", Journal of Clinical Oncology, 18, 547 — 561.
- Silverman, LB., Declerk, L., Gelber, RD., Kimball V., Dalton, V., Asselin, B.L., Barr, RD., et al. (2000) "Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981 — 1995)", Leukemia, 14, 2247–2256.
- Sacchi, S., Kantarjian, H.M., O'Brien, S., Cortes, J., Rios, MB., Giles, F.J., et al. (1999) "Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients", Cancer, 86, 2632–2641.
- Wadhwa, J., Szydlo, R.M., Apperley, J.F., Chase, A., Bua, M., Marin, D., et al. (2002) "Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia", Blood, 99, 2304–2309.